Fifty-four college women with symptoms of lower urinary tract infections were randomly treated, 25 with 500 mg of ceftriaxone in a single intramuscular dose and 29 with 160 mg of trimethoprim-800 mg of sulfamethoxazole orally twice daily for 7 days. At 1 week after treatment, 23 patients (92%) in the ceftriaxone group and 28 patients (96%) in the trimethoprim-sulfamethoxazole group were cured. Responses of the patients with positive or negative antibody-coated bacteria tests were not significantly different. Four patients (16%) in the ceftriaxone group developed diarrhea and malaise. One patient (4%) in the trimethoprim-sulfamethoxazole group had medication discontinued because of headaches. Leukopenia was found in one patient (4%) in the ceftriaxone group and four patients (14%) in the trimethoprim-sulfamethoxazole group.
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Single-dose regimens of a variety of antimicrobial agents have been found effective in the treatment of acute uncomplicated urinary tract infections (UTIs) (2, 13, 24; A. Iravani and G. A. Richard, Pediatr. Res. 15:443, 1981) . Cephalosporins are effective against most common urinary tract pathogens (16) , but their administration as a single dose for UTIs is controversial (5, 15, 23, 27) . Ceftriaxone is a new, parenterally administered cephalosporin with an expanded antibacterial activity (6, 10, 21) . Its plasma elimination half-life is about 8 h (four times longer than that of other cephalosporins), and it is excreted in its active form in high concentrations in the urine (7, 25, 26, 28) .
The purposes of this trial were (i) to compare the efficacy and safety of a single intramuscular dose of ceftriaxone with multiple oral doses of trimethoprim-sulfamethoxazole for treatment of UTIs in college women, (ii) to relate therapeutic responses to the results of antibody-coated bacteria test (ACBT), and (iii) to assess the emergence of resistant Enterobacteriaceae in the urogenital and rectal areas.
MATERIALS AND METHODS
Patient criteria. Fifty-four college women with symptoms of acute cystitis were enrolled in the study at the Kidney Clinic of the University of Florida Student Health Service. The major criteria for inclusion in this study were (i) the presence of at least one bacterium in each random highpower microscopic field of uncentrifuged and unstained samples of two urine specimens and (ii) 2105 CFU of the same bacterium per ml in each of the two urine specimens. Excluded were pregnant or lactating women, patients who had received antimicrobial therapy during the preceding week, and those with fever (238°C), flank pain, impaired renal or liver function, radiographically proven obstructive uropathy, history of glucose 6-phosphate dehydrogenase deficiency, or allergy to cephalosporins, trimethoprim, or sulfonamides.
Collection and processing of specimens. Two clean-catch, midstream urine specimens were obtained from each patient within 24 Clinical evaluation and urine cultures were repeated on the second day of treatment in the trimethoprim-sulfamethoxazole group. In both groups they were repeated at 2 days and at 1, 4, 8, and 12 weeks after the end of treatment.
During the first 3 days of treatment, patients in the trimethoprim-sulfamethoxazole group used a diary to record the time medication was taken; both groups recorded the times of voiding and the time of resolution of dysuria and urgency. Complete disappearance of the symptoms by the end of treatment in the trimethoprim-sulfamethoxazole group and by 1 week after treatment in the ceftriaxone group was termed a clinical cure; persistence of symptoms was a clinical failure. (10) 25 (87) Bacteriological responses were classified as follows: (i) dysuria, frequency, urgency, or suprapubic pain. The mean short-term cure, when urine culture was sterile by day 2 of duration of symptoms before the initiation of therapy was treatment and remained sterile at 1 week after treatment or 2.5 days in the ceftriaxone group and 2.7 days in the contained <104 CFU/ml; (ii) long-term cure, when urine trimethoprim-sulfamethoxazole group. Seven patients (28%) cultures were sterile or contained <104 CFU/ml through 4 in the ceftriaxone group and three patients (10%) in the weeks after treatment; (iii) reinfection, when a different trimethoprim-sulfamethoxazole group had vaginal candidipathogen emerged at a count of 2105 CFU/ml of urine asis. Fourteen patients (56%) in the ceftriaxone group and 18 beyond 2 days after treatment ended; (iv) relapse, when an patients (62%) in the trimethoprim-sulfamethoxazole group organism similar to the initial pathogen appeared at a count had no history of UTIs (P > 0.10); the remaining patients of -105 CFU/ml of urine beyond 2 days and through 4 weeks had had one to three UTIs in the preceding 12 months. after treatment; (v) superinfection, when a different pathoUrinary pathogens are listed in Table 1 ; all were susceptible gen emerged at 2105 CFU/ml of urine up to 2 days after to both ceftriaxone and trimethoprim-sulfamethoxazole. aminotransferase (serum glutamic-pyruvic transaminase), alIn the ceftriaxone group, all 25 patients had sterile urine kaline phosphatase, bilirubin, creatinine, urea nitrogen, and cultures at day 2 after treatment. Cure rates at 1 and 4 weeks complete cell count before treatment and 1 week after after treatment were 92 and 80%, respectively. In the treatment in the ceftriaxone group and 2 days after the end of trimethoprim-sulfamethoxazole group, all 29 patients had treatment in the trimethoprim-sulfamethoxazole group. sterile urine cultures 2 days after treatment began and 2 days Statistical analysis. The life table method and the chiafter treatment ended. The cure rates at 1 and 4 weeks after square test were used to analyze the data (8, 14) . treatment were 93 and 87%, respectively ( Table 2 . Patients with a positive ACBT had a less favorable response than those with a negative ACBT in both treatment groups, but the differences were not statistically significant.
Bacterial colonization in the urogenital and rectal flora. All bacterial isolates were susceptible in vitro to trimethoprimsulfamethoxazole before and after treatment. In rectal cultures, one ceftriaxone-resistant E. coli isolate and one ceftriaxone-resistant Enterobacter aerogenes isolate were isolated before treatment and two ceftriaxone-resistant Citrobacterfreundii were isolated after treatment. The number of patients with bacterial colonization of the urogenital area decreased after treatment with ceftriaxone (P < 0.01). The number of patients with bacterial colonization in the urogenital (P < 0.01) and rectal (P < 0.05) areas decreased after treatment in the trimethoprim-sulfamethoxazole group (Table 3).
Side effects. Occasional minor discomfort occurred at the site of ceftriaxone injection. One patient, because of allergy to lidocaine, received ceftriaxone diluted in 2 ml of sterile water. She immediately developed severe pain in the injection site, became pale, and lost her pulse and respiration. However, she responded rapidly to cardiopulmonary resuscitation. Four other patients (16%) experienced a combination of mild to moderate diarrhea (three patients), abdominal cramps (two), headache (one), malaise (one), chills (one), and swollen eyelids (one). In the trimethoprim-sulfamethoxazole group, one patient (4%) developed severe headache and nausea; her medication was discontinued at the third day of treatment. (15) with a single oral dose of cefaclor. They attributed the unfavorable results of these two trials to a high incidence of pyelonephritis in their patients. Ronald et al. (24) and Fairley et al. (13) used a bladder wash-out technique to localize the site of infection. They found favorable results when kanamycin was given as a single intramuscular dose to patients with lower UTIs, but poor responses in those with upper UTIs. In our study, patients with fever and flank pain were excluded, although asymptomatic UTIs could be present (12) . Patients with positive ACBTs suggestive of upper UTIs responded less favorably to treatment in both ceftriaxone and trimethoprimsulfamethoxazole groups. However, the differences were not statistically significant.
The presence of a few ceftriaxone-resistant bacteria in the rectal flora before and after treatment was not associated with active UTIs and appeared to be of no clinical significance. The decrease in the frequency of urogenital colonization with Enterobacteriaceae after ceftriaxone treatment may have been due to its high concentration in urine (26) and possibly its high concentration in vaginal secretions as well. Our finding of decreased frequency of rectal and urogenital colonization with Enterobacteriaceae after trimethoprim-sulfamethoxazole treatment is in agreement with previous reports (17, 20) . Judson et al. found no adverse reactions from single intramuscular injections of ceftriaxone (19) . In our study, patient acceptance of a single intramuscular injection of ceftriaxone in lidocaine was good. However, mild to moderately severe systemic adverse reactions, similar to those reported with longer courses of ceftriaxone (4, 6, 10, 11) occurred in four patients. The transient leukopenia that we found in four patients with trimethoprim-sulfamethoxazole treatment has been previously reported in children (1). Vaginal candidiasis, sensitivity reactions, and emergence of resistant bacteria were not a problem.
This study suggests that a single intramuscular dose of ceftriaxone is as effective as a 7-day course of trimethoprimsulfamethoxazole in the treatment of uncomplicated UTIs in young women. We believe that single-dose antimicrobial treatment should be monitored with repeat urine cultures at 1 and 4 weeks after treatment to assure eradication of the infection.
